TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02008708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livestock Microfinance
Description: Participants randomized to the microfinance group receive the pig loan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control Group
Description: Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
Study: NCT04025606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
Study: NCT03896828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-macronutrient meal
Description: Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-macronutrient meal
Description: Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-macronutrient meal
Description: Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches.
Study: NCT03143192

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Micropulse Laser
Description: Aflibercept injection with Micropulse laser.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: Aflibercept injection with Sham Laser
Study: NCT01774994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion for measurement of metabolism
Study: NCT03405376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
Study: NCT00738361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
Study: NCT03459222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study: NCT05520606

Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region

Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
Study: NCT00003330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study: NCT02953678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or methylprednisolone
Description: Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
Study: NCT03081039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight.
Study: NCT04633642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Description: Every week during a six-week treatment period

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical group
Description: Every week during a six-week treatment period
Study: NCT03442010

Intervention type: OTHER
Intervention: Detection of adverse drug events
Description: Detection of adverse drug events
Study: NCT02356211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Assessment
Description: The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
Study: NCT02346682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
Study: NCT01901848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Description: NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy (NRT)
Description: NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care for Smoking Cessation (ICSC)
Description: ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care for Smoking Cessation (ICSC)
Description: ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
Study: NCT04267250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg by mouth (PO) once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg by mouth (PO) once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Oral tablet containing 30 mcg EE and 150 mcg LN.
Study: NCT01901848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smokefreeVET
Description: SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smokefreeVET
Description: SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
Study: NCT03459222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02640300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Switching to clozapine with immediate or gradual antipsychotic discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Switching to clozapine with immediate or gradual antipsychotic discontinuation
Study: NCT01008826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: broccoli sprouts extract
Description: Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
Study: NCT04267250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Oral tablet containing 30 mcg EE and 150 mcg LN.
Study: NCT03611530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coqun® ophthalmic solution
Description: Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
Study: NCT02200341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRT-PsyEd
Study: NCT04561037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field therapy (PEMFT)
Description: PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMJ physical therapy program
Description: TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
Study: NCT01778712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Description: The development of a lifestyle program intended to intervene on the individual, social network and community over two years
Study: NCT02711826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyclonal Regulatory T Cells
Description: Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy, Kidney

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy, Kidney
Study: NCT02711826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IS regimen conversion
Description: Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
Study: NCT01177852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine + dropropizine + pseudoephedrine
Description: Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
Study: NCT00744744

Intervention type: OTHER
Intervention: informational intervention
Description: Patient educational information

Intervention type: OTHER
Intervention: questionnaire administration
Description: Survey
Study: NCT01177852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
Description: Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml
Study: NCT04480814

Intervention type: DIAGNOSTIC_TEST
Intervention: PIK3CA kit
Description: Prospective investigation of clinical samples for evaluation of IVD clinical performance

Intervention type: DIAGNOSTIC_TEST
Intervention: PIK3CA kit
Description: Prospective investigation of clinical samples for evaluation of IVD clinical performance
Study: NCT00145041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection
Description: Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
Study: NCT01550978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100 System
Description: AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
Study: NCT00839540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micafungin
Description: 100 mg qd by slow IV infusion for 24 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 200 mg qd by slow IV infusion for 24 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: 70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Study: NCT04324242

Intervention type: OTHER
Intervention: abdominal hallowing maneuver
Description: abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO

Intervention type: OTHER
Intervention: abdominal hallowing maneuver
Description: abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
Study: NCT02984319

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry versus placebo concentrate
Description: Acute cherry concentrate
Study: NCT00744744

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Survey

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: Survey
Study: NCT00430313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Stimulation of Yongquan (K1) Acupoint
Description: Electro-stimulation at a inactive site on the bottom of the foot (a placebo site).
Study: NCT02235116

Intervention type: OTHER
Intervention: Survey
Study: NCT01726920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naratriptan + naproxen
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg
Study: NCT04131101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Organizing
Description: The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
Study: NCT03793920

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
Study: NCT02984319

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cherry versus placebo concentrate
Description: Acute cherry concentrate
Study: NCT03793920

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
Study: NCT03891329

Intervention type: DEVICE
Group type: OTHER
Intervention: Acticor/Rivacor ICDs/CRT-Ds
Description: pre-defined device programming, measurements and follow-up schedule

Intervention type: DEVICE
Group type: OTHER
Intervention: Plexa S DX
Description: Implantation, measurements and follow-up schedule
Study: NCT00992563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension
Study: NCT01726920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naratriptan
Description: Tablets containing naratriptan 2,5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: Tablets containing naproxen 500 mg
Study: NCT01758393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT03634358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar scissors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic scalpel
Study: NCT02546674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.